Can Congenital Adrenal Hyperplasia Be Inherited? Carrier Risk
At a Glance
If you have congenital adrenal hyperplasia caused by gene variants, you pass one variant to each child. A child usually develops CAH only when the other parent carries a variant in the same gene, so genetic counseling and testing can clarify risks and family-planning options.
In this answer
3 sections
If you have congenital adrenal hyperplasia (CAH) caused by a specific gene variant, you will pass one of your variant genes to your biological children. However, whether your child is born with the condition depends mostly on your partner’s genetics [1].
CAH is a group of autosomal recessive conditions, meaning it requires two disease-causing genetic changes (called pathogenic variants)—one inherited from each parent—to be present in the same gene for a person to have the condition [1]. The most common form of CAH is 21-hydroxylase deficiency, caused by variants in the CYP21A2 gene [1]. If your partner does not carry a pathogenic variant in the exact same gene that causes your CAH, your children will be carriers (they will inherit one variant from you) but will usually not have the condition [1].
If your CAH is caused by CYP21A2 and your partner is confirmed to be a carrier of a variant in the same gene, there is a 50% chance with each pregnancy that your child will inherit two variants and have CAH [1]. If your partner also has CAH caused by the same gene, all of your children will inherit two variants [1]. Note that having two pathogenic variants does not always mean a child will have the severe “classic” form of CAH; the specific variants inherited help predict the severity, though they cannot perfectly forecast the exact symptoms [2].
Carrier Risk in the General Population
Many people are carriers of a CAH gene variant and do not know it, as carriers usually do not show symptoms of classic CAH [1]. The likelihood of your partner being a carrier depends on their ancestry and which specific variants are considered [3] [4].
For example, the classic form of 21-hydroxylase deficiency is estimated to occur in roughly 1 in 15,000 to 20,000 births globally [5] [6]. However, the carrier frequency for milder, non-classic variants is much higher in certain populations. One study estimated that 15% of people of Ashkenazi Jewish descent and roughly 9.5% of the US Caucasian study population were carriers of a non-classic variant [4]. In some specific geographic or founder populations (communities originating from a small group of ancestors), the prevalence can be even higher [7]. Because these are only population averages, they do not replace the need for specialized genetic testing for your partner.
Genetic Counseling and Partner Testing
If you have CAH or know you are a carrier and are planning a family, medical guidelines recommend preconception genetic counseling and partner testing [8] [9].
A genetic counselor is a specialized healthcare professional who can help you understand your risks based on your exact genetic variants and family history [10]. Before testing your partner, it is usually necessary to molecularly confirm your own specific genetic variants [11].
Testing for CYP21A2 is technically complex. The gene has a highly similar pseudogene (a piece of DNA that looks like the gene but does not function) located right next to it, which can cause false results in standard tests [12] [13]. Standard carrier screening panels might miss complex structural changes or deletions. It is important that your partner receives testing through a laboratory experienced with CAH that looks closely at the full CYP21A2 gene [9] [12]. It is also important to know that no test is perfect; a negative result significantly reduces the risk that your partner is a carrier, but it cannot completely eliminate the risk of rare or hard-to-detect variants [13].
Family Planning Options and Pregnancy Considerations
If testing reveals that your partner is a carrier, a genetic counselor can walk you through your family planning options. These may include:
- Natural conception with or without prenatal diagnosis.
- Prenatal diagnosis, such as chorionic villus sampling (CVS) or amniocentesis, to test the fetus during pregnancy [9] [14]. These are invasive procedures with some risks.
- In vitro fertilization (IVF) with PGT-M (preimplantation genetic testing for monogenic diseases), which screens embryos for the specific CAH variants present in your family before implantation [9] [12]. This requires knowing the exact familial variants and building a custom test.
Pregnancy with CAH: If you are the one with CAH, you must carefully manage your condition during pregnancy. Do not stop or change your glucocorticoid or mineralocorticoid replacement therapy without consulting your endocrinologist [8]. Pregnancy, severe morning sickness, and labor can cause physical stress that requires coordinated care between your endocrinologist and an obstetrician experienced in high-risk pregnancies to adjust your medication dosages and prevent an adrenal crisis [8].
Common questions in this guide
If I have CAH, will my children automatically have it?
What is the chance that my partner carries a CAH gene variant?
If my CAH involves CYP21A2, what genetic test should my partner have?
Does a negative CAH carrier test eliminate my partner’s risk?
What family-planning options are available if my partner is a CAH carrier?
How should CAH be managed during pregnancy?
If both parents have CAH from the same gene, what is the child’s risk?
Related questions
Show more
Get notified when new evidence is published on Congenital adrenal hyperplasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia.
Parsa AA, New MI
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):2-11 doi:10.1016/j.jsbmb.2016.06.015.
PMID: 27380651 - 2
Recent advances in biochemical and molecular analysis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Choi JH, Kim GH, Yoo HW
Annals of pediatric endocrinology & metabolism 2016; (21(1)):1-6 doi:10.6065/apem.2016.21.1.1.
PMID: 27104172 - 3
The Spectrum of Genetic Defects in Congenital Adrenal Hyperplasia in the Population of Cyprus: A Retrospective Analysis.
Neocleous V, Fanis P, Toumba M, et al.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2019; (51(9)):586-594 doi:10.1055/a-0957-3297.
PMID: 31505704 - 4
Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians.
Hannah-Shmouni F, Morissette R, Sinaii N, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(11)):1276-1279 doi:10.1038/gim.2017.46.
PMID: 28541281 - 5
Congenital Adrenal Hyperplasia in the Mediterranean: A Concise Overview.
Fanis P, Skordis N, Tomazou M, et al.
Pharmaceuticals (Basel, Switzerland) 2026; (19(5)) doi:10.3390/ph19050741.
PMID: 42198415 - 6
Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.
Miller WL
Hormone research in paediatrics 2019; (91(6)):416-420 doi:10.1159/000501396.
PMID: 31450227 - 7
The prevalence and genotype of 21-hydroxylase deficiency in the Croatian Romani population.
Dumic KK, Grubic Z, Kusec V, et al.
Frontiers in endocrinology 2023; (14()):1170449 doi:10.3389/fendo.2023.1170449.
PMID: 37324261 - 8
The importance and implications of preconception genetic testing for accurate fetal risk estimation in 21-hydroxylase congenital adrenal hyperplasia (CAH).
Rama Chandran S, Loh LM
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2019; (35(1)):28-31 doi:10.1080/09513590.2018.1490399.
PMID: 30044156 - 9
The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum.
Maher JY, Gomez-Lobo V, Merke DP
Reviews in endocrine & metabolic disorders 2023; (24(1)):71-83 doi:10.1007/s11154-022-09770-5.
PMID: 36399318 - 10
Issues with the Detection of Large Genomic Rearrangements in Molecular Diagnosis of 21-Hydroxylase Deficiency.
Concolino P
Molecular diagnosis & therapy 2019; (23(5)):563-567 doi:10.1007/s40291-019-00415-z.
PMID: 31317337 - 11
Genetics of Congenital Adrenal Hyperplasia.
Hannah-Shmouni F, Chen W, Merke DP
Endocrinology and metabolism clinics of North America 2017; (46(2)):435-458 doi:10.1016/j.ecl.2017.01.008.
PMID: 28476231 - 12
EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency.
Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W
European journal of human genetics : EJHG 2020; (28(10)):1341-1367 doi:10.1038/s41431-020-0653-5.
PMID: 32616876 - 13
Nationwide carrier screening for congenital adrenal hyperplasia: integrated approach of CYP21A2 pathogenic variant genotyping and comprehensive large gene deletion analysis.
Suwanlikit Y, Panthan B, Chitayanan P, et al.
BMC medical genomics 2025; (18(1)):18 doi:10.1186/s12920-025-02089-5.
PMID: 39856693 - 14
Prenatal genetic testing and treatment for congenital adrenal hyperplasia.
Simpson JL, Rechitsky S
Fertility and sterility 2019; (111(1)):21-23 doi:10.1016/j.fertnstert.2018.11.041.
PMID: 30611408
This page is for informational purposes only and does not constitute medical advice. Discuss your CAH genetic results, pregnancy plans, and medication changes with a genetic counselor and endocrinologist; pregnancy care may also involve an obstetrician experienced in high-risk pregnancies.